Cargando…

Erratum to: Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study

Detalles Bibliográficos
Autores principales:	Escobar, Yolanda, Cajaraville, Gerardo, Virizuela, Juan Antonio, Álvarez, Rosa, Muñoz, Andrés, Olariaga, Olatz, Tamés, María José, Muros, Begoña, Lecumberri, María Jose, Feliu, Jaime, Martínez, Purificación, Adansa, Juan Carlos, Martínez, María José, López, Rafael, Blasco, Ana, Gascón, Pere, Calvo, Virginia, Luna, Pablo, Montalar, Joaquín, Del Barrio, Patricia, Tornamira, María Victoria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2015
Materias:	Erratum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4713940/ https://www.ncbi.nlm.nih.gov/pubmed/26166000 http://dx.doi.org/10.1007/s00520-015-2842-2

Ejemplares similares

Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study
por: Escobar, Yolanda, et al.
Publicado: (2015)

The Effect and Safety of Olanzapine on Nausea and Vomiting in Children Receiving Moderately Emetogenic Chemotherapy
por: Eghbali, Aziz, et al.
Publicado: (2023)

Open-label observational study to assess the efficacy and safety of aprepitant for chemotherapy-induced nausea and vomiting prophylaxis in Indian patients receiving chemotherapy with highly emetogenic chemotherapy/moderately emetogenic chemotherapy regimens
por: Hingmire, Sachin, et al.
Publicado: (2015)

Prolonged usage of fosaprepitant for prevention of delayed chemotherapy-induced nausea and vomiting(CINV) in patients receiving highly emetogenic chemotherapy
por: Gao, Ai, et al.
Publicado: (2023)

Influence of menopause on chemotherapy‐induced nausea and vomiting in highly emetogenic chemotherapy for breast cancer: A retrospective observational study
por: Yokokawa, Takashi, et al.
Publicado: (2023)

Single‐dose NEPA versus an aprepitant regimen for prevention of chemotherapy‐induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy
por: Zelek, Laurent, et al.
Publicado: (2023)

Chemotherapy-Induced Nausea and Vomiting
por: Rapoport, Bernardo Leon, et al.
Publicado: (2015)

Ramosetron versus Palonosetron in Combination with Aprepitant and Dexamethasone for the Control of Highly-Emetogenic Chemotherapy-Induced Nausea and Vomiting
por: Kang, Jin Hyoung, et al.
Publicado: (2020)

SEOM Clinical Guideline update for the prevention of chemotherapy-induced nausea and vomiting (2021)
por: Majem, Margarita, et al.
Publicado: (2022)

Delayed Chemotherapy-Induced Nausea and Vomiting: Pathogenesis, Incidence, and Current Management
por: Rapoport, Bernardo L.
Publicado: (2017)

A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy‐Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy
por: Zelek, Laurent, et al.
Publicado: (2021)

Correction to: SEOM Clinical Guideline update for the prevention of chemotherapy-induced nausea and vomiting (2021)
por: Majem, Margarita, et al.
Publicado: (2022)

Investigation of Nausea and Vomiting in Cancer Patients Undergoing Chemotherapy
por: Lavdaniti, Maria, et al.
Publicado: (2014)

Chemotherapy- and cancer-related nausea and vomiting
por: Warr, D.G.
Publicado: (2008)

Personalized Estimate of Chemotherapy-Induced Nausea and Vomiting: Development and External Validation of a Nomogram in Cancer Patients Receiving Highly/Moderately Emetogenic Chemotherapy
por: Hu, Zhihuang, et al.
Publicado: (2016)

Efficacy of triple antiemetic therapy (palonosetron, dexamethasone, aprepitant) for chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based, moderately emetogenic chemotherapy
por: Miya, Toshimichi, et al.
Publicado: (2016)

The incidence of anticipatory nausea and vomiting after repeat cycle chemotherapy: the effect of granisetron.
por: Aapro, M. S., et al.
Publicado: (1994)

Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial
por: Boccia, Ralph, et al.
Publicado: (2013)

The Effectiveness of Ginger in the Prevention of Nausea and Vomiting during Pregnancy and Chemotherapy
por: Lete, Iñaki, et al.
Publicado: (2016)

Management of Patients With Chemotherapy-Induced Nausea and Vomiting
por: Barbour, Sally Yowell
Publicado: (2017)

Chemotherapy-Induced Nausea and Vomiting: Updates and Recommendations
por: Viale, Pamela Hallquist
Publicado: (2018)

Efficacy of the granisetron transdermal system for the control of nausea and vomiting induced by highly emetogenic chemotherapy: a multicenter, randomized, controlled trial
por: Sun, Der Sheng, et al.
Publicado: (2023)

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial(†)
por: Weinstein, C., et al.
Publicado: (2016)

Prophylactic treatment for delayed chemotherapy-induced nausea and vomiting after non-AC based moderately emetogenic chemotherapy: a systematic review of randomized controlled trials
por: van der Vorst, Maurice J. D. L, et al.
Publicado: (2015)

Multicenter, placebo‐controlled, double‐blind, randomized study of fosnetupitant in combination with palonosetron for the prevention of chemotherapy‐induced nausea and vomiting in patients receiving highly emetogenic chemotherapy
por: Sugawara, Shunichi, et al.
Publicado: (2019)

Metoclopramide, Dexamethasone, or Palonosetron for Prevention of Delayed Chemotherapy‐Induced Nausea and Vomiting After Moderately Emetogenic Chemotherapy (MEDEA): A Randomized, Phase III, Noninferiority Trial
por: van der Vorst, Maurice J.D.L., et al.
Publicado: (2020)

A deep learning‐based interpretable decision tool for predicting high risk of chemotherapy‐induced nausea and vomiting in cancer patients prescribed highly emetogenic chemotherapy
por: Zhang, Jingyue, et al.
Publicado: (2023)

SEOM Clinical Guideline update for the prevention of chemotherapy-induced nausea and vomiting (2016)
por: de las Peñas, R., et al.
Publicado: (2016)

Risk factors associated with antineoplastic chemotherapy-induced nausea and vomiting
por: Simino, Giovana Paula Rezende, et al.
Publicado: (2020)

Multicenter phase IV study of palonosetron in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with non-Hodgkin lymphomas undergoing repeated cycles of moderately emetogenic chemotherapy
por: Choi, Brian S., et al.
Publicado: (2014)

Efficacy of Olanzapine-Triple Antiemetic Regimen in Patients with Gastrointestinal Tumor and High Risk of Chemotherapy-Induced Nausea and Vomiting Receiving Moderately Emetogenic Chemotherapy: A Retrospective Study
por: Wu, Xuan, et al.
Publicado: (2020)

Efficacy and Safety of Thalidomide As a Pre-Medication of Chemotherapy-Induced Nausea and Vomiting (CINV) Following Highly Emetogenic Chemotherapy (HEC): A Systematic Review and Meta-Analysis
por: Xie, Jiyi, et al.
Publicado: (2022)

Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE
por: Hata, Akito, et al.
Publicado: (2022)

Prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitant
por: Olver, Ian N
Publicado: (2008)

Impact of tumour burden on chemotherapy-induced nausea and vomiting.
por: Hursti, T. J., et al.
Publicado: (1996)

Recent advances in pharmacotherapy of chemotherapy-induced nausea and vomiting
por: Bhandari, Prasan R.
Publicado: (2012)

Olanzapine: An Antiemetic Option for Chemotherapy-Induced Nausea and Vomiting
por: Brafford, Megan V., et al.
Publicado: (2014)

Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting
por: Navari, Rudolph M.
Publicado: (2015)

Dronabinol for chemotherapy-induced nausea and vomiting unresponsive to antiemetics
por: May, Megan Brafford, et al.
Publicado: (2016)

Cheaper Options in the Prevention of Chemotherapy-Induced Nausea and Vomiting
por: Gyawali, Bishal, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_83m6a2df93ujb8noj9s8qe6e51